Importantly, expression of TrkA and TrkC is positively correlated with favorable biological features of neuroblastoma [14,15], whereas increased expression of TrkB and BDNF is associated with an unfavorable prognosis in patients concomitant with MYCN-amplification [16,17]. Here, NTRK2 is linked to neuroblastoma.